PSNL · Personalis, Inc.

Current Thesis

PSNL is the ultra-sensitive MRD (minimal residual disease) liquid-biopsy operator its NeXT Personal tumor-informed ctDNA blood test detects recurrence at single-digit parts-per-million. The narrative leg is Medicare-reimbursement TAM unlock + best-in-class clinical data → biopharma-MRD revenue inflection, and that theme is genuinely ACCELERATING. The problem is the tape, not the story. The cluster of catalysts that drove a +70% run into late May (four Medicare decisions + ASCO data) has already fired, and on 2026-06-05 the stock pushed to a fresh 52-week high of $12.53 intraday, then reversed to close $10.75 (-11.16%) on ~4.1M shares a failed breakout above the prior $11.85 high. A fresh entry now buys a post-catalyst parabola that just showed its first distribution candle, with no hard binary until the Q2 print (~early Aug). Theme ACCELERATING; entry stretched and freshly rejected.

Bull Case

• Clinical volume inflecting: Q1 2026 (reported 2026-05-08) ran 7,800+ clinical tests, +258% YoY / +26% sequential; total revenue $15.47M beat the $14.49M consensus by ~6.8%.
• Medicare TAM unlock four MolDX decisions in 2026: 2026-05-13 coverage for immunotherapy monitoring across late-stage solid tumors; 2026-05-19 fourth decision adding Stage II-III TNBC/HER2+ breast neoadjuvant monitoring; prior NSCLC Stage I-III surveillance. Reimbursement is the gating variable for MRD adoption.
• Data moat reinforced at ASCO 2026 (2026-05-29 → 06-02): colorectal 100% surveillance sensitivity / 82% landmark at 4 weeks post-surgery; single-digit-ppm ctDNA detection across CRC, lung, melanoma, ovarian, endometrial, renal; TRACERx NSCLC podium slot.
• Back-half ramp committed: FY2026 guide reaffirmed $78-80M (+26% YoY), with biopharma-MRD targeted at $20-21M vs Q1 $3.1M implies a ~5x H2 ramp on now-signed large pharma trials.
• Squeeze fuel present: ~11% of float short; a -11% reversal on a heavily-shorted name can flip back to a cover-driven bounce if support holds.

Bear Case

• Catalysts spent + failed breakout. The 2026-06-05 reversal off a new high ($12.53 → close $10.75, -11%) is the first crack after a vertical move the easy reimbursement and ASCO headlines are now behind it.
• Deeply unprofitable: EPS -$1.02 trailing, Q1 -$0.29 missed the -$0.27 estimate; ~$15.5M/qtr revenue base supports a ~$1.13B market cap (~14x FY26 sales — rich for diagnostics).
• Revenue is back-half loaded and execution-dependent: $3.1M MRD in Q1 must become ~$17-18M across the rest of FY26; any trial-start slip breaks the inflection math.
• Crowded field, structural pricing pressure: Natera (Signatera), Guardant (Reveal), Exact (Oncodetect) and Tempus all chase MRD reimbursement and volume.
• No scheduled hard catalyst for ~30 days afterglow fades fast on a beta-2.28 low-float name that ran this hard.

Setup & Price Structure

• Price: $10.75 close (2026-06-05), -11.16% on the day; after-hours $10.87. Day's range $10.38-$11.95; intraday high $12.53 set a new 52-week high before the reversal. 52w range $3.84-$12.53.
• Momentum: the up-leg is now ~+70% off the May base; the June 5 session is a bearish reversal/shooting-star that rejected the breakout zone. 20-SMA still above 60-SMA (mid-term trend intact), but price remains well above the 50-day MA extended.
• Resistance: $11.95 (June 5 intraday close-area) → $12.53 (new 52w high); a reclaim and hold above $12.53 on volume re-arms continuation. Support: breakout shelf ~$8.50-9.00 (rising 20-EMA), then prior base ~$6.70, structural $5.49 / $3.84.
• Read: peak post-catalyst sentiment + stretched above MA + a failed breakout. The clean re-entry is a higher-low pullback that holds the 20-EMA (~$8-9) or a decisive volume reclaim above $12.53 not chasing into the rejection.

Catalyst Calendar (next 30 days)

• No scheduled hard binary in the 2026-06-07 → 2026-07-07 window. Q1 already printed (2026-05-08); the next earnings binary is Q2 2026 (~early Aug, est.), outside this window earnings blackout applies ≤3 trading days prior.
• Unscheduled MolDX/CMS coverage expansions have been the surprise drivers all spring (4 decisions in 2026); another determination could land anytime but has no posted date.
• June healthcare-conference circuit (Jefferies/Goldman/William Blair, early-mid June, est.) possible presentation/fireside, soft sentiment catalyst only, not a binary.
• Net: the window is a catalyst vacuum; price action governs, and the June 5 rejection is the live signal.

What Would Change Our Mind

• Bullish re-arm: a daily/weekly close back above $12.53 on expanding volume (reclaims the failed breakout) turns the rejection into a shakeout and validates continuation.
• Constructive pullback: a higher-low that holds the rising 20-EMA (~$8-9) with declining-volume down days the textbook second-entry for a name whose theme is still accelerating.
• Thesis break (stand aside / fade): weekly close below $8.00 (gives back >50% of the May breakout, loses the 20-EMA); FY2026 guide cut below $78M; or Q2 print showing biopharma-MRD run-rate tracking under the $20-21M FY target.
• A new MolDX/CMS coverage decision would reset the catalyst clock and could justify revisiting even an extended tape.

Correlation Notes

• MRD/liquid-biopsy peer complex: trades in sympathy with Natera (NTRA), Guardant (GH), Exact Sciences (EXAS) and Tempus (TEM) on reimbursement and clinical-data headlines; a CMS decision for any peer can move the group.
• High-beta diagnostics/biotech: beta 2.28 means PSNL amplifies XBI / IWM risk-on/risk-off swings; a small-cap-growth drawdown hits this harder than the tape.
• Low float + ~11% short interest: moves are exaggerated in both directions vertical on good news, air-pocket reversals (as on June 5) on exhaustion.